Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.


Investor type Venture Capital
Founders Jay W. Schmelter


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 76
Average round size
The average size of a deal this fund participated in
Portfolio companies 46
Rounds per year 3.45
Lead investments 13
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 20
Key employees 6
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Therapeutics
  • Pharmaceutical

RiverVest is the famous VC, which was founded in 2000. The venture was found in North America in United States. The main department of described VC is located in the St Louis.

The fund has specific favorite in a number of founders of portfolio startups. In case when startup counts 3 or 4 of the founder, the chance for it to get the investment is meager. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. We can highlight the next thriving fund investment areas, such as Health Diagnostics, Manufacturing. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight ZS Pharma, Arch Oncology, OncoResponse.

The fund was created by Jay W. Schmelter. The overall number of key employees were 6.

Opposing the other organizations, this RiverVest works on 3 percentage points less the average amount of lead investments. The top activity for fund was in 2014. Despite it in 2019 the fund had an activity. The fund is constantly included in 2-6 investment rounds annually. Deals in the range of 10 - 50 millions dollars are the general things for fund. The higher amount of exits for fund were in 2011. Considering the real fund results, this VC is 6 percentage points more often commits exit comparing to other organizations.

The typical case for the fund is to invest in rounds with 5-6 participants. Despite the RiverVest, startups are often financed by Cultivation Capital, Alta Partners, PTV Healthcare Capital. The meaningful sponsors for the fund in investment in the same round are Alta Partners, Arnerich Massena & Associates, 3x5 Special Opportunity Fund. In the next rounds fund is usually obtained by 3x5 Special Opportunity Fund, Alta Partners, Arnerich Massena & Associates.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of RiverVest:
Typical Co-investors
RiverVest is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after RiverVest:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation California, San Francisco, United States
Alphabit Fund California, San Francisco, United States
Beijing Liyue Jinshi Investment Center (LP) Beijing, Beijing, China
FMC.COM Investment Holdings China, Hong Kong, Hong Kong Island
Globalive Technology -
Hudson Structured Capital Management Connecticut, Stamford, United States
HyogoBenderEngineering Himeji, Hyogo Prefecture, Japan
Infinite Capital LLC Ohio, Rocky River, United States
INV Fintech New York, New York, United States
Invaluable Allston, Massachusetts, United States
Knightsgate Ventures -
Leoch Battery China, Guangdong, Shenzhen
Link Hui Capital -
ORBITAL Space Investment Vehicle -
Pechel Industries Partenaires France, Ile-de-France, Paris
PIMCO California, Newport Beach, United States
Shanghai Qianyi Investment Management China, Shanghai
Southern Ontario Fund for Investment in Innovation (SOFII) -
Winterpoint Alabama, Birmingham, United States

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Good Therapeutics

Life Science
$8M30 Dec 2021 Seattle, Washington, United States

Venture Med Group

Health Care
Medical Device
23 Nov 2021 Minnesota, United States


Health Care
Medical Device
$100M02 Nov 2021 San Diego, California, United States

Scout Bio

Health Care
$33M19 Oct 2021 Philadelphia, Pennsylvania, United States


$172M15 Jul 2021 St Louis, Missouri, United States


$35M23 Jun 2021 San Francisco, California, United States

Standard Bariatrics

Health Care
Medical Device
$35M01 Jun 2021 Cincinnati, Ohio, United States

$50M18 May 2021 Portland, Oregon, United States

Arch Oncology

$105M27 Apr 2021 California, United States
SeQure Dx Announces $17.5M Series A Funding

– SeQure Dx is a gene-editing diagnostics company.
– It announced a $17.5m Series A funding.
– The funding was led by RiverVest Venture Partners and Mass General Brigham Ventures along with Digitalis Ventures, Casdin Capital, KdT Ventures, Bold Capital Partners and Alexandria Venture Investments.
– Funds will be used for initial company development leading to establishment of a full-service laboratory providing off-target gene-editing analysis for use in drug development, clinical trials and ultimately patient evaluation prior to therapy.
– SeQure Dx was founded on exclusive licensure of GUIDE-seq, ONE-seq and related assay technologies for detection of off-target gene-editing events.

Wugen Raises $172 Million to Advance Clinical Stage Memory NK Cell Platform, Progress Best-In-Class AML Program, and Initiate Multiple Solid Tumor Trials

– Wugen, Inc. completed an oversubscribed $172m Series B financing led by Abingworth and Tybourne Capital Management, and joined by new investors Fidelity Management and Research Company, Intermediate Capital Group, Sands Capital, Aisling Capital Management, Alexandria Venture Investments, Velosity Capital and Falcon Edge Capital.
– Existing investors, including RiverVest Venture Partners, LYZZ Capital, and Lightchain Capital, also participated.
– In connection with the financing, Bali Muralidhar, M.D., Ph.D., Managing Partner at Abingworth, Bosun Hau, Managing Director at Tybourne Capital Management, and Peter Kiener, Ph.D., Venture Partner at ICG, will join Wugen’s Board of Directors.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent RiverVest?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: